Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SURITAL vs PHRENILIN FORTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
Induction of anesthesia,Maintenance of anesthesia as part of balanced anesthesia,Adjunct to regional anesthesia,Control of convulsive states (off-label)
Tension-type headache
Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
Terminal elimination half-life 2-8 hours (mean 4.5 h) in adults; prolonged in hepatic impairment.
Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease.
Primarily hepatic metabolism via microsomal enzyme oxidation (CYP2B6, CYP3A4) to inactive metabolites; minor renal excretion.
Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2.
Primarily renal excretion of metabolites; <1% unchanged. Minor biliary/fecal elimination.
Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally.
~70% bound to albumin.
Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin.
1.5-2.5 L/kg; indicates extensive tissue distribution.
Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg.
IM: ~90%.
Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete).
No specific GFR-based adjustments; metabolized primarily in liver. Caution in severe renal impairment due to potential accumulation of inactive metabolites.
Not formally established. Acetaminophen component: avoid in severe renal impairment (Cr Cl <10 m L/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for Cr Cl 10-50 m L/min.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and titrate to effect. Child-Pugh C: Contraindicated or use with extreme caution with reduced doses (e.g., 25-50% of normal).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity.
Induction: 3-6 mg/kg IV. Maintenance: 1-2 mg/kg IV as needed. Use with caution; not recommended for neonates.
Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred.
Reduce dose by 30-50% due to decreased clearance and increased sensitivity. Administer slowly and titrate to effect.
Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly.
WARNING: RESPIRATORY DEPRESSION AND CARDIAC ARREST. SURITAL may cause severe respiratory depression or apnea, especially with rapid administration. Resuscitative equipment and personnel trained in airway management must be immediately available. Avoid intra-arterial injection due to risk of arteriospasm, thrombosis, and gangrene.
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
Monitor respiratory and cardiac function continuously; use with caution in patients with respiratory compromise, hypotension, shock, or hepatic/renal impairment; may cause laryngospasm, bronchospasm, or hypotension; avoid extravasation; use with caution in porphyria.
Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment.
Absolute: Known hypersensitivity to barbiturates, acute intermittent porphyria, severe respiratory insufficiency, status asthmaticus, and conditions where general anesthesia is contraindicated.
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
No specific food interactions reported for Surital (thiamylal). However, patients should avoid consuming grapefruit or grapefruit juice for 24 hours before and after administration, as it may theoretically inhibit cytochrome P450 metabolism, although significant interactions are not well-documented.
Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital.
Pregnancy Category D (positive evidence of human fetal risk). First trimester: Risk of congenital anomalies (limb defects, CNS malformations) based on animal studies and limited human data. Second/third trimester: Increased risk of preterm labor, fetal bradycardia, neonatal respiratory depression, and withdrawal syndrome. Avoid use during pregnancy unless clearly needed.
First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk.
Excretion into breast milk is unknown; M/P ratio not established. Due to high lipid solubility, potential for significant transfer. Consider risks of neonatal CNS depression. Use with caution; monitor infant for sedation, poor feeding, and respiratory depression. Alternative agents preferred.
Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts.
Increased volume of distribution and hepatic metabolism in pregnancy may require higher induction doses and more frequent maintenance doses. However, due to fetal risks, avoid use in pregnancy unless absolutely necessary. If used, start at lower range (e.g., 3-4 mg/kg IV induction) and titrate to effect. No established dose adjustment guidelines; individualize based on clinical response and close monitoring.
Increased renal clearance and volume of distribution in pregnancy may reduce acetaminophen and caffeine levels; no standard dose adjustment recommended. Butalbital: increased clearance due to hepatic enzyme induction and increased Vd; monitor for reduced efficacy; adjust dose based on clinical response. Avoid supratherapeutic doses.
Surital (thiamylal) is an ultra-short-acting barbiturate used for induction of anesthesia. Due to its high lipid solubility, onset of action is rapid (<30 seconds). It is contraindicated in porphyria and should be used with caution in patients with hepatic impairment, as it is metabolized in the liver. Extravasation causes tissue necrosis; use a large vein for IV administration. Respiratory depression and laryngospasm are common during induction. Surital has no analgesic properties and may cause myocardial depression at high doses. For short procedures, it provides rapid awakening but with potential residual sedation.
Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment.
This medication is used to put you to sleep before surgery or certain procedures.,You may feel dizzy or drowsy for several hours after receiving this drug; do not drive or operate machinery for at least 24 hours.,Avoid alcohol for at least 24 hours after receiving this medication as it can increase side effects.,Inform your healthcare provider if you have a history of porphyria, liver disease, or respiratory problems.,Do not breastfeed for at least 24 hours after administration without consulting your doctor.,Notify your doctor immediately if you experience severe pain, redness, or swelling at the injection site.,You may experience temporary confusion or memory loss after waking up; this is normal and should resolve.
Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen.,Avoid alcohol while taking this medication to prevent liver toxicity.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Do not use with other products containing acetaminophen to avoid overdose.,If you have a history of substance abuse, inform your doctor; this drug can be habit-forming.,Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SURITAL vs PHRENILIN FORTE, answered by our medical review team.
SURITAL is a Barbiturate Anesthetic that works by SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.. PHRENILIN FORTE is a Barbiturate Combination Analgesic that works by Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SURITAL and PHRENILIN FORTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SURITAL is: Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.. The standard adult dose of PHRENILIN FORTE is: 1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SURITAL and PHRENILIN FORTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SURITAL is classified as Category C. Pregnancy Category D (positive evidence of human fetal risk). First trimester: Risk of congenital anomalies (limb defects, CNS malformations) based on animal studies and limited hu. PHRENILIN FORTE is classified as Category C. First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.